Acquisition Completed

Neurocrine Biosciences acquisition of Soleno Therapeutics

US$2.9bn equity value

Announced 6 Apr 2026 · NASDAQ: SLNO · US$53.00 cash per share

Advisers

Neurocrine Biosciences

Acquirer

Financial adviser
Legal adviser
Target
Soleno Therapeutics
Acquirer
Neurocrine Biosciences
Target based in
United States
Buyer based in
United States
Completed
18 May 2026
Sector
Biotech
Tags
Biotech, Rare Disease, Pharma

In the league tables

Similar deals

All biotech deals →

Sources

Suggest a correction

A missing adviser, a wrong role or a different outcome. A link to a public source helps.